Study identifies flap striae risk influenced by climatic conditions
June 15th 2014A retrospective study including more than 614,000 eyes undergoing femto-LASIK at a single practice over a 5-year period identified a flap striae incidence of 0.85% overall, however a climate conditions influence was also noted.
Study: Endophthalmitis low despite antibiotic-free intravitreal injection
June 10th 2014Analyses of safety data from Diabetic Retinopathy Clinical Research Network (DRCR.net) trials show a very low rate of endophthalmitis can be achieved in eyes receiving intravitreal drug injections using protocol that does not use topical antibiotics, said Abdhish R. Bhavsar, MD.
Allergan responds to board shake-up attempt by Valeant, Pershing Square
June 5th 2014Allergan has fired back in response to Pershing Square Capital Management’s announcement that it will hold a special meeting with Allergan shareholders, where it will ask to oust six of Allergan’s nine directors in an attempt to pass Valeant Pharmaceuticals International’s re-revised unsolicited takeover proposal of the company.
Allergan acknowledges revised, unsolicited Valeant proposal
June 3rd 2014Allergan has publicly acknowledged that Valeant Pharmaceuticals International, along with Pershing Square Capital Management, have made a second revised, unsolicited proposal to acquire all of the outstanding shares of the company.
Faster visual recovery next goal for refractive surgery
June 3rd 2014Although patients undergoing thin-flap LASIK performed with modern femtosecond and excimer lasers can expect excellent vision on the day after surgery, faster visual recovery might enhance the procedure’s appeal, according to Daniel S. Durrie, MD.
IATS report weighs IOL, contact lens for aphakia
June 1st 2014The Infant Aphakia Treatment Study evaluated outcomes after unilateral cataract surgery during early infancy in children randomly assigned to primary aphakic correction with an IOL or contact lens. Visual acuity results and clinical findings during follow-up through age 5 were recently published.
Lifitegrast promising for patients using artificial tears
June 1st 2014John Sheppard, MD, highlights results of a phase III randomized, double-masked, placebo-controlled trial of lifitegrast in dry eye patients previously on artificial tears. He presented these results, a subset analysis of the OPUS-1 phase III trial, at the 2013 meeting of the American Society of Cataract and Refractive Surgery.
Ophthalmologists to see new payment models, increased patient access
June 1st 2014Increased patients and patient access, new payment models, and the rise of comparative effectiveness research top the list of challenges that ophthalmologists will face in the future, according to William L. Rich, III, MD, FACS.
Sustained drug delivery moving toward clinical use
June 1st 2014“New Horizons in Glaucoma Drug Delivery” session reviewed nine development programs. Some companies are focusing on micro- and nano-scale particles, others on gels and solid drug depots. All aim for controlled, steady state delivery over specific time periods to enhance drug delivery to the target tissue and improve therapeutic outcomes.